• Science
    • Scientific Overview
    • Rett Syndrome
    • Oncology
    • Wilson Disease
  • Pipeline
  • Team
  • News
  • Careers
  • Contact
DepYmed
  • Science
    • Scientific Overview
    • Rett Syndrome
    • Oncology
    • Wilson Disease
  • Pipeline
  • Team
  • News
  • Careers
  • Contact

Harnessing the Potential of Phosphatase Inhibitors for Therapeutic Development

LEARN MORE
Picture
 
Shape Divider - Style triangle

NOVEL THERAPEUTICS

Novel Therapeutics

DepYmed is currently developing potent inhibitors of the enzyme PTP1B as therapeutics for cancer and rare diseases.  In addition, DepYmed has developed a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer.  ​
Shape Divider - Style triangle

OUR TECHNOLOGY

DepYmed is developing novel therapeutics targeting the role of protein tyrosine phosphatases in signaling pathways involved in the pathology of multiple diseases.
​
Advancing two orally bioavailable small molecules into clinical trials for:
  • Rett Syndrome
  • Cancer
  • Wilson Disease
​We are building a library of novel selective PTP1B (phosphatase) inhibitors with therapeutic potential for other major metabolic, inflammatory and neurodegenerative diseases.
Shape Divider - Style triangle
Picture
Shape Divider - Style triangle

RECENT NEWS

Picture
DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome
By DepYmed, Inc. | March 19, 2024
DepYmed to Meet with Investors at the BIO CEO and Investor Conference
By DepYmed, Inc. | February 21, 2024
DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference
By DepYmed, Inc. | February 7, 2024
DepYmed to Meet with Investors at the Life Sciences Summit in New York City October 11, 2023
By DepYmed, Inc. | October 3, 2023
DepYmed to Meet with Investors  at the BioFuture Conference in New York City October 4-6, 2023
By DepYmed, Inc. | September 27, 2023
DepYmed to Meet with Investors  at the LSX World Congress USA in Boston on September 13-14, 2023
By DepYmed, Inc. | September 7, 2023
DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
By DepYmed, Inc. | June 14, 2023
DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting
By DepYmed, Inc. | May 31, 2023
SEE ALL NEWS
Shape Divider - Style triangle
DepYmed, Inc.
3 Bioscience Park Drive
Farmingdale, NY 11735
@ 2022 DepYmed, Inc.
  • Science
    • Scientific Overview
    • Rett Syndrome
    • Oncology
    • Wilson Disease
  • Pipeline
  • Team
  • News
  • Careers
  • Contact